UNSPSC 51122405: Pentaerythritol tetranitrate/phenobarbital

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CV250. This VA Drug Class (CV250) classifies this compound as belonging to the group ANTIANGINALS.

UNSPSC 51122405 Pentaerythritol tetranitrate/phenobarbital is a Commodity code that in practice encompasses emergency life-support medications and generic pharmaceuticals supplied to state and local government health systems, fire rescue services, and pharmacy benefit programs. State and local solicitations under this code request specific medication line items with firm pricing, FDA compliance, expiration-date requirements, and delivery guarantees; vendors typically supply through established pharmaceutical wholesalers and must maintain pharmaceutical-grade manufacturing certifications and comprehensive liability insurance. Issuing bodies include municipal purchasing departments (fire rescue and emergency medical services), state health and human services agencies, and multistate cooperative purchasing alliances that aggregate demand across member jurisdictions. The scope spans both emergency-care medications for immediate use and bulk generic pharmaceuticals for ongoing institutional distribution.

Geographic activity centers on Florida, Texas, and Minnesota based on recent solicitations. The City of Tampa Purchasing Department issued IFB 26P00188 in April 2026 for Advanced Life Support Medications (Labetalol, Epinephrine, Adenosine, Diltiazem) needed by Tampa Fire Rescue, with an estimated contract value of $40,000 and bids due April 8, 2026; the award included a Small Local Business Enterprise sheltered-market designation with a 5 percent bid discount not to exceed $10,000. The Texas Health and Human Services Commission posted RFI HHS0017013 in early April 2026 seeking vendor capabilities for a Therapeutic Pharmacy Initiative direct-to-manufacturer prescription program, representing early-stage market research before formal RFP issuance. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products distributed across state and local facilities in Minnesota and Oregon, with proposals due March 26, 2026 and contract awards effective July 1, 2026; MMCAP requires vendors to partner with AmerisourceBergen (Cencora), Cardinal Health, or Morris & Dickson as authorized wholesalers and imposes a 3 percent administrative fee on all purchases.